Progression through the cell cycle is controlled by the induction of cyclins and activation of cognate cyclindependent kinases. The human hepatitis B virus-X (HBV-X) protein functions in gene expression alterations, in the sensitization of cells to apoptotic killing and deregulates cell growth arrest in certain cancer cell types. We have pursued the mechanism of growth arrest in Hep3B cells, a p53-mutant human hepatocellular carcinoma (HCC) cell line. In stable or transient HBV-X transformed Hep3B cells, HBV-X increased protein and mRNA levels of the cyclin-dependent kinase inhibitor (CDKI) p21 wa¯/cipl , increased binding of p21 wa¯/cipl with cyclin-dependent kinase 2 (CDK2), markedly inhibited cyclin E and CDK2 associated phosphorylation of histone H1 and induced the activation of a p21 promoter reporter construct. By using p21 promoter deletion constructs, the HBV-X responsive element was mapped to a region between 71185 and 71482, relative to the transcription start site. Promoter mutation analysis indicated that the HBV-X responsive site coincides with the ets factor binding sites. These data indicate that in human hepatocellular carcinoma cells, HBV-X can circumvent the loss of p53 functions and induces critical downstream regulatory events leading to transcriptional activation of p21 wa¯/cipl . As a consequence, there is an increased chance of acquisition of mutations which can enhance the genesis of hepatomas. Our results also emphasize the chemotherapeutic potential of p21 wa¯/cipl inhibitors, particularly in the HBV-X infected hepatoma which lacks functional p53. Oncogene (2000) 19, 3384 ± 3394.
Progression through the cell cycle is controlled by the induction of cyclins and activation of cognate cyclindependent kinases. The human hepatitis B virus-X (HBV-X) protein functions in gene expression alterations, in the sensitization of cells to apoptotic killing and deregulates cell growth arrest in certain cancer cell types. We have pursued the mechanism of growth arrest in Hep3B cells, a p53-mutant human hepatocellular carcinoma (HCC) cell line. In stable or transient HBV-X transformed Hep3B cells, HBV-X increased protein and mRNA levels of the cyclin-dependent kinase inhibitor (CDKI) p21 wa¯/cipl , increased binding of p21 wa¯/cipl with cyclin-dependent kinase 2 (CDK2), markedly inhibited cyclin E and CDK2 associated phosphorylation of histone H1 and induced the activation of a p21 promoter reporter construct. By using p21 promoter deletion constructs, the HBV-X responsive element was mapped to a region between 71185 and 71482, relative to the transcription start site. Promoter mutation analysis indicated that the HBV-X responsive site coincides with the ets factor binding sites. These data indicate that in human hepatocellular carcinoma cells, HBV-X can circumvent the loss of p53 functions and induces critical downstream regulatory events leading to transcriptional activation of p21 wa¯/cipl Introduction Factors which determine whether eukaryotic cells continue to proliferate or cease dividing and dierentiating appear to operate mainly during the G1 phase of the cell cycle (Pardee, 1989) . Key transitions into the cell cycle are regulated by a family of serine/ threonine protein kinases termed cyclin-dependent kinases (CDKs) that consist of a catalytic subunit, CDK and a regulatory subunit, cyclin. CDKs are regulated at multiple levels including the induction and degradation of cyclin proteins and association with members of a group of heterologous small regulatory proteins, belonging to two families of CDK inhibitor proteins (p16 and p21) (Morgan, 1995) . CDK inhibitors can negatively regulate cell cycle progression in response to a variety of antiproliferative signals including DNA damage, dierentiation, contact inhibition and senescence (Grana and Reddy, 1995; Kamb et al., 1994) . The ®rst of these negative regulatory proteins to be identi®ed was the p53-activated DNA damage inducible p21 protein, a universal inhibitor of cyclin-CDK complexes and DNA replication (El-Deiry et al., 1993; Xiong et al., 1993; Dulic et al., 1994) . In addition to direct transcriptional induction by the tumor suppressor p53, various other signals have been reported to induce p21 expression in the absence of wild-type p53. For example, TGF-b (Datto et al., 1995a) , phorbol 12-myristate-13 acetate and okaic acid (Biggs et al., 1996; Zeng and El-Deiry, 1996; Zeng et al., 1997) directly stimulate the gene promoter, resulting in G1 arrest. Experiments have also provided evidence for p53-independent regulation of p21 in vivo, and have been implicated in its expression in growth arrest associated with terminal dierentiation (Erhart and Pittman, 1998) . Though overexpression of p21 wa¯/cipl is associated with apoptosis in many dierent cases (Yonish-Rouach et al., 1991; Shaw et al., 1992; Lowe et al., 1993) , it often protects cells against apoptosis by arresting cell cycle progression in the G1 phase, like cell resistancies to chemotherapeutic agents (Zhang et al., 1995a; Gorospe and Holbrook, 1996) .
Hepatitis B virus (HBV) causes acute and chronic liver cell injury and in¯ammation and is closely associated with liver cancer (Chisari, 1996; Kim et al., 1991; Terradillos et al., 1997) . Among the four gene products, HBsAg, HBcAg, HBxAg and polymerase encoded by the four ORFs in HBV, HBxAg is a protein, approximately 154 amino acids long, which has been detected with high frequency in liver cells from patients with chronic hepatitis, cirrhosis and liver cancer and might be a prime candidate for mediating the HBV pathologic eect. HBV-X has been shown to alter the coordinate balance between proliferation and programmed cell death, being able to either induce or block apoptosis in a dosedependent manner (Terradillos et al., 1998) . In contrast to these pro-apoptotic eects of HBV-X protein, evidence of the anti-apoptotic eect of HBV-X protein has also been demonstrated. A recent report on the antiapoptotic eect of HBV-X protein showed that HBV-X inhibits caspase 3 activity (Gottlob et al., 1998) resulting in resistance to various apoptotic stimuli such as growth factor depletion, tumor necrosis factor-a or anti-Fas antibody administration. In addition to these proapoptotic or anti-apoptotic eects of HBV-X, a growth arrest eect was also demonstrated in our experiment. In this study we demonstrated that HBV-X induces growth arrest at the G1 phase in a p53-independent manner by activating p21 wa¯/cipl . HBV-X transfection in Hep3B cells increased mRNA and protein levels of p21 wa¯/cipl , increased binding of p21 wa¯/cipl with CDK2, inhibited cyclin E and CDK2-associated phosphorylation of histone H1 and induced the activation of p21 promoter. These results demonstrated that HBV-X is able to exert a strong growth arrest eect in hepatoma cells in a p53-independent pathway in cell cycle progression.
Results

HBV-X prolongs the G1/S transition of the hepatoma cells
In this experiment, stable transfectants of the HBV-X gene in hepatoma (Hep3B-6X, 8X) cell lines were used. Transfected HBV-X gene integration and expression in Hep3B-6X and 8X cell lines were detected by Southern and Northern blotting and its biological activity were detected by chloramphenicol acetyl transferase (CAT) assay using various kinds of promoter-CAT reporter systems (Lee et al., 1998a) . HBV-X protein expression in these cell lines were also con®rmed by immunouorescence microscopy. The HBV-X transfectant enhanced AP-1 transcription factor binding to its target DNA (Lee et al., 1998a) . Therefore, Hep3B-6X and 8X cell lines are not only stable but also have speci®c biological functions. Cells (5 ± 6610 3 ) were plated in 6-well plates (Nunc, Roskilde, Denmark) and the total cell number in each well was counted every day to check the eect of X-expression on the cell growth in each of the transfectants. Figure 1a shows the cell growth of X-transfected Hep3B cells. Both of the X-transfected cells showed growth inhibition compared to the Hep3B cell. To determine the reasons for the reduced rate of cellular proliferation, we then conducted cell cycle analysis of Hep3B and Xtransfectants using¯ow cytometry.
As shown in Figure 1b , HBV-X induced the accumulation of cells in the G1 phase of the cell cycle in Hep3B-6X and Hep3B-8X cell lines. The kinetics of the cell cycle progression demonstrated that X induced growth inhibition of Hep3B cells by arresting the cells in the G1/S phase.
HBV-X expression is uncoupled from apoptosis
We examined the apoptotic responses of Hep3B cells to X-treatment (Figure 2a ). Hep3B (lane 1), transiently Xexpressing Hep3B (lane 2) and permanent X-expressing Hep3B (6X and 8X) cells (lane 3 and 4) were examined for the degree of DNA fragmentation. For positive control, we used vitamin K3 treated Hep3B cells which showed apoptosis (lane 5). As shown in Figure 2a neither transiently X-transfected nor permanent Xtransfected Hep3B cells showed any induction of nucleosomal DNA ladder, while vitamin K3 induced apoptosis in Hep3B cells. In order to con®rm the DNA laddering experiment, TUNEL assay was performed with the same conditions as in Figure 2a . TUNEL positive cells were only detected on Figure 2b -5 which con®rms the fact that only VK3-treated Hep3B cells showed apoptosis.
Levels of CDK2, CDK4 and cyclin E protein are unchanged following HBV-X treatment The G1/S transition is regulated by D-type cyclins which bind to and activate CDK4 and CDK6 and cyclin E, which activates CDK2. Because HBV-X arrests Hep3B cells in G1, we tested whether HBV-X decreased protein levels of CDK2, CDK4 or cyclin E. As demonstrated in Figure 3a , Western blot analysis of the samples obtained from HBV-X transfected for dierent periods showed no changes in protein levels even after 64 h of exposure to HBV-X. It should be noted, however, that the actual eects of HBV-X on these proteins may be larger because of the nonlinearity of the chemiluminescence detection system. HBV-X inhibits CDK2 and cyclin E-associated kinase activity Figure 3b -I showed that treatment of Hep3B cells with HBV-X for varying time periods resulted in a highly signi®cant reduction in CDK2 and cyclin E-associated kinase activity in a time-dependent manner while the Figure 3 Eect of HBV-X on the levels of CDK2, CDK4 and cyclin E protein, and CDK2-dependent and cyclin E-dependent kinase activity. (a) Eect of HBV-X on the levels of CDK2, CDK4 and cyclin E protein. Hep3B cells were transfected with 5 mg of HBV-X expression vector for the times indicated. Total cell lysates were prepared and Western analysis was performed using anti-CDK2, anti-CDK4 or anti-cyclinE antibody and the bound antibody was visualized by chemilluminescence (ECL; Amersham). (b) Eect of HBV-X on CDK2 kinase and cyclin E-associated kinase activity. After 16, 24, 48 and 64 h of HBV-X transfection, cell lysates were immunoprecipitated (IP) with anti-CDK2 or cyclin E antibody and kinase activity was assayed using histone H1 as substrate (I). For control, pMAMneo vector was used (II) control vector (pMAMneo) transfected Hep3B cells for varying time periods (Figure 3b -II) did not show any changes in CDK2 and cyclin E-associated kinase activity. These results indicated that the inhibition of CDK2 and cyclin E-associated kinase activity might involve binding of a CDK inhibitor protein to the CDK2-cyclin E complex.
HBV-X induces p21 protein and association of p21 with CDK2
Western blot analysis showed that HBV-X induced an increase in the level of the CDK inhibitor p21 ( Figure  4a ). HBV-X expression resulted in an increase of p21 expression after 16 h and continued to increase after 64 h (Figure 4a ). In eukaryotic cells the regulation of the cell cycle is determined by CDKs complexed with their catalytic subunit cyclin or functional levels of CDK Inhibitors (CDKI). Therefore the growth arrest in speci®c phases of the cell cycle depends on the decrease in the levels of CDKs and/or cyclins in speci®c phases or induction of CDKI expression leading to an increase in its binding to and subsequent inactivation of CDK-cyclin complexes. The results obtained in our study showed that the HBV-X treatment on Hep3B cells does not result in a decrease of CDKs (CDK2 and 4) or cyclin E expression ( Figure 3a ) but induced p21 wa¯/cipl expression ( Figure  4a ). So, the possibility of p21 wa¯/cipl binding to CDKs and the inactivation of its kinase activity were tested. As shown in Figure 4b HBV-X induces p21 mRNA through a p53-independent mechanism G1/S arrest is associated with an elevated cellular p21 wa¯/cipl level whose expression can be upregulated by wild-type p53 or by a p53-independent pathway. To examine the mechanism by which HBV-X induces p21
wa¯/cipl , we performed RT ± PCR and Northern analysis of HBV-X on the level of p21 transcripts. The HBV-X expression resulted in an increase of p21 expression after 16 h and continued to increased after 72 h ( (Figure 3b ). For the control, pMAM-neo were used for transfection . p53 acts at the transcriptional level to increase p21 expression in response to DNA damage (El-Deiry et al., 1993) . In Hep3B cells the p53 gene has been reported to be truncated and p53 protein absent. As a control, we performed Western blot analysis for p53 and p21
wa¯/cipl expression in dierent hepatoma cell lines, including Hep3B. Figure 5c shows the results of HBV-X eect on p53 and p21 expression on four dierent hepatoma cell lines and an A549 adenoma cell line. HepG2, A549 and Huh7 cells which express wildtype p53 and PLC/PRF/5 cells which express mutant type p53 expressed constant amounts of p53 and p21 proteins. The p53 and p21 expression were not aected by HBV-X. In Hep3B cells which harbor structural p53 derangements and do not express any p53, show enhanced levels of p21 wa¯/cipl expression by HBV-X. These data demonstrate that HBV-X is regulating the level of p21 mRNA through a p53-independent mechanism.
Transcriptional control of p21 wafl/cipl induction following X-treatment of hepatoma cells Since HBV-X increased the level of p21 wa¯/cipl mRNA in cells, we investigated the direct eect of HBV-X upon the p21 wa¯/cipl promoter using the p21-CAT reporter which contains chloramphenicol acetyl transferase (CAT) reporter gene under the control of 2.4 Kb p21 wa¯/cipl promoter in Hep3B cells. The eect of HBV-X on expression of p21 promoter-CAT construct was dose-dependent ( Figure 6a ). As the concentration of Xexpression vector increases (1, 2 and 3 mg) it increases the transcription of p21-CAT reporter constructs (Figure 6a ). To examine the stimulatory eect of HBV-X on p21-CAT in dierent cell lines, 2 mg of wild-type p21-CAT construct was contransfected with 2 mg of the control expression vector (pMAMneo) or HBV-X expression vector (pMAM-HX) in Hep3B, HepG2, PLC/PRF/5 and A549 cell lines (Figure 6b) . In all four cell lines, the CAT activity was increased by HBV-X more than the control expression vector. These results show that HBV-X transactivates the p21 promoter not only in hepatoma cell lines (Hep3B, HepG2, PLC/PRF/5) but also in the adenocarcinoma (A-549) cell line, indicating that X-transactivation of Figure 4 HBV-X induces the cyclin-dependent kinase inhibitor p21 and association of p21 with CDK2. (a) Hep3B cells were transfected with HBV-X for the time indicated and total cell lysates were subjected to Western blot analysis using anti-p21 antibody and enhanced chemiluminescence detection. For control, pMAMneo control vector were transfected (V). (b) Hep3B cells were transfected with HBV-X for the time indicated and the cell lysates were immunoprecipitated (IP) with anti-CDK2 antibody, separated on SDS-polyacrylamide gels, transferred to nitrocellulose and incubated with anti-p21 antibody followed by enhanced chemiluminescence detection the p21 promoter is a general phenomena in all cell lines.
To further demonstrate that HBV-X enhances transcription of the p21 wa¯/cipl gene in a p53-independent manner, deletion mutants of p21 wa¯/cipl promoter regions were used for contransfection into Hep3B cells. These plasmids were cotransfected with either a control expression plasmid (pMAMneo) or the HBV-X expression plasmid (pMAM-HX) into the p53 negative Hep3B cells. The level of CAT activity was determined 48 h after transfection. The activities of constructs D 0 (72327), D 2 (71482), D 3 (71185) and D 4 (7292) showed 11.1, 9.6, 0.9, and onefold induction, respectively by HBV-X (Figure 6c-I ).
Since the sequences between 71482 and 71185 which showed HBV-X-responsiveness to the p21 wa¯/cipl promoter, contain Ets binding sites, the importance of these binding sites for HBV-X activity was investigated. To examine the role of the Ets binding sites in HBV-X-mediated transcriptional regulation, the Ets binding site was inactivated by changing the base pair sequences (GGAA ? GAGA) of the site (Figure 6c -II). The eect of HBV-X on the Ets binding site mutant was examined by cotransfection of the plasmid into Hep3B cells with and without an HBV-X expression vector (Figure 6c-II) . Wild-type construct (p21 D 2 71482) activities were induced 11.4-fold by HBV-X, whereas mutant construct (p21 D2-Ets-mt) wa¯/cipl in cells cultured with transfection (+) or no transfection (7) of HBV-X for 48 h were determined using Western blot analysis was induced only 1.3-fold. Thus the change of GGAA to GAGA inactivates the HBV-X responsiveness to p21 promoter. These results con®rm that HBV-X can stimulate transcription of the p21 promoter through Ets binding sites.
Stimulation of p21
wafl/cip1 promoter by Ets-1
To determine whether Ets binds to p21 promoter, gel mobility shift assay using Ets1 Ab or Ets2 Ab were used using 23 mer (5'-TCAGCTGCGTTAGAGAGA-GAAGAC-3') Ets binding oligomer from p21 promoter fragment as probe (Figure 7a ). Nuclear extracts from Hep3B cells were used. Mutated 23 mer Ets binding oligomer was used as a control. As shown in Figure 7a , Ets1 binds with high anity to Ets probe but does not bind to Ets mutated probe (Figure 7a lanes 1, 2 and 5, 6). One microgram each of Ets1 and Ets2 antibody were used for super-shift gel retardation experiment (lanes 3 and 4). Both Ets1 and Ets2 antibody treated nuclear extracts showed supershifted band (lanes 3 and 4) on gel retardation experiment. These results con®rm that Ets1 and Ets2 binds to p21 promoter. To determine directly whether the p21 promoter was involved in mediating Ets-directed transcription, the eect of Ets-1 on transcription was examined in Hep3B cells. The p21-CAT chimeric constructs were cotransfected with a Ets-1 expression vector and the level of CAT activity was determined (Figure 7b ). The activity of constructs were induced 2.6; 3.5; 0.8-and 1.1-fold increased respectively, by Ets-1. These ®ndings suggest that the Ets site is located between 71482 and 71185 in the p21 promoter and Ets can bind to this fragment, while the bound Ets is transcriptionally active.
Discussion
Our data show that HBV-X enhances the expression of p21 wa¯/cipl and delays cell cycle progression in the G1 phase via a p53-independent pathway. HBV-X increased protein and RNA levels of p21 wa¯/cipl , increased binding of p21 wa¯/cipl with CDK2, markedly inhibited cyclinE and CDK2-associated phosphorylation of histone H1 and activated the p21-promoter. HBV-X upregulates the p21 wa¯/cipl through the HBV-X responsive element on the p21 wa¯/cipl promoter region. The HBV-X responsive element identi®ed is located within the 71185 to 71482 site and identi®ed as ets site while the responsive elements by TFG-b (Datto et al., 1995a) , vitamin D3 (Datto et al., 1995b) , phorbol ester, okadaic acid (Bigg et al., 1996; Zeng and ElBeing, 1996) , STAT1 (Chin et al., 1996) and butyrate (Nakano et al., 1997) on p21 promoter are located in dierent positions.
The HBV-X is a promiscuous transactivator implicated in cell growth and death in the development of HCC. The pro-apoptotic eects of HBV-X protein have been described (Gottlob et al., 1998) . A direct dose-dependent apoptotic function of HBV-X has been demonstrated in transiently transfected liver cell lines (Terradillos et al., 1998) . HBV-X protein acutely sensitizes cells to apoptotic killing when expressed during viral replication independent of other genes (Werness et al., 1990; Su and Schneider, 1997; Slagle et al., 1996; Elmore et al., 1997) . Cells that were resistant to apoptotic killing by high doses of tumor necrosis factor-a, a cytokine associated with liver damage during HBV infection, were made sensitive to very low doses of TNF-alpha by HBV-X (Su and Schneider, 1997) . Deregulation of cell cycle checkpoint control by HBV-X was reported (Benn and Schneider, 1995) . HBV-X stimulates cell cycle progression, shortening the emergence of cells from quiescence (G0) and entry into S phase and accelerating transit through checkpoint controls at G0/G1 and G2/M thus participate in the selection of cells that are genetically unstable, some of which would accumulate unrepaired transforming mutations (Benn and Schneider, 1995) . Modulation of the apoptosis by the interactions of HBV-X protein and p53 gene product has also been reported (Elmore et al., 1997; Takada et al., 1997; Wang et al., 1994) . Anti-apoptotic actions of HBV-X protein as a potent caspase 3 inhibitor has been described (Gottlob et al., 1998) . HBV-X transfected hepatoma cells (Hep) are resistant to various apoptotic stimuli such as growth factor depletion, tumor necrosis factor-a or anti-Fas antibody administration. In these cells, HBV-X prevented DNA fragmentation and cell death in the absence of de-novo protein synthesis with a similar eciency as the competitive caspase 3 substrates inhibitors VAD-FMK and DEVD-FMK. Based on these reports, HBV-X can exert multifunctional aspects of gene regulations in various dierent cell environments which depends on the amounts of HBV-X produced in each dierent physiological conditions as Terradillos suggested (Terradillos et al., 1998) .
The ets gene family encodes unique transcription factors that have a common ETS DNA binding domain (Lautenberger et al., 1992; Seth et al., 1992) . At least 12 distinct est-related genes have been isolated form various species (Lautenberger et al., 1992) . Overexpression of the ets-1 and ets-2 genes transform NIH3T3 cells and induce tumors in nude mice (Seth et al., 1989; Seth and Papas, 1990) . Two other ets-related genes, the Spi-1/PU.1 and the ERBG/Fli-1, were also shown to have a direct role in neoplasia, since these two genes were found to be activated by spleen focusforming virus (SFFV) and murine leukemia virus (MULV) proviral integration in erythroleukemias (Moreau-Gachelin et al., 1989; Ben-David et al., 1991) . Recently, it is reported that regulation of the N-acetyl glucosaminyl transferase V (Gn T-V) gene which appears to play a crucial role in tumor metastasis, is mediated by ets transcription factors in a cell-speci®c manner in human and murine cancer cells (Ko et al., 1999) . These ®ndings suggest that Ets-1 is a multifunctional transcription factor. Since HBV-X act through ets site of p21 promoter, the relations between HBV-X and ets need to be identi®ed. One possibility is the direct interactions of ets transcription factor with HBV-X resulting in the activation of p21 as in the case of Maguire et al. (1991) . Another possibility is the activations of ets binding to its binding site through the post-transcriptional protein modi®cations through signal transduction pathways (Lee et al., 1998b) . It has been known that Ets1 and Ets2 are speci®c nuclear targets of Ras signaling events and that phosphorylation of a conserved threonine residue is a necessary molecular component of Ras-mediated activations of these transcription factors (Yang et al., 1996) . The identi®cation of mechanisms underlying the HBV-X and ets interactions resulting in the p21 activations is in progress in this laboratory. Our study showed that HBV-X enhances the expression of p21 waf1/cip1 and delays cell cycle progression in the G1 phase via a p53-independent pathway thus preventing apoptosis, the most potent natural defence mechanism against cancer. These results suggest that HBV-X could enhance the carcinogenicity of DNA-damaging agents by conferring a survival advantage to cells (preneoplastic) which have survived but have not been completely repaired. p21 waf1/cip1 has been found to play an important role in growth arrest that follows exposure to various stressful insults (Gorospe and Holbrook, 1996; Xiong et al., 1993) . p21 waf1/cip1 has also been reported to participate in apoptosis (Gorospe and Holbrook, 1996) . Indeed, increased p21 waf1/cip1 expression has been correlated with enhanced death in some instances (Gorospe and Holbrook, 1996) but more often, its elevated expression has been associated with increased cell survival (El-Deiry et al., 1994) . A high level of p21 waf1/cip1 expression was found in many tumors which showed resistancy to chemotherapy (Kobayashi et al., 1995) . Enhanced p21 waf1/cip1 expression has been correlated with poor treatment prognosis in myeloid leukemias, while low levels of p21 waf1/cip1 expression is associated with better responsiveness to chemotherapy. Since HBV-X prevents apoptosis, the most potent natural defense mechanism against cancer, by upregulating the expression of p21 waf1/cip1 , HBV-X could not only prevent premature death of infected cells thereby facilitating viral replication, spread or persistence, but also increase the resistence of chemotherapy treatment with the otherwise poor treatment prognosis in liver cancers. Our results support the facts that resistance to apoptosis is an important factor in the development of malignant HCC and also suggests that either chemotherapeutic approaches directly aimed at preventing p21 waf1/cip1 or antagonists of the signaling pathways that lead to p21 waf1/cip1 expression could lead to improved elimination of HCC. p53 modulations of the cytotoxic eect of common antitumors agents (where the cells lacking wild-type p53 are resistant and cells expressing p53 wild-type are sensitive to anticancer agents and undergo cell death by apoptosis), suggested that the status of p53 in certain cancers, provides a genetic basis for drug resistance (Zhang et al., 1995b) . Novel therapeutic agents for patients whose tumors harbor p53 mutations or lacking wild-type p53 (where the antitumor agents frequently respond poorly) need to be developed under the basis of p53 status in the tumors. Our results support the fact that resistance to apoptosis is an important factor in the development of malignant HCC and also suggests that either chemotherapeutic approaches directly aimed at preventing p21 waf1/cip1 or antagonists of the signaling pathway that lead to p21 waf1/cip1 expression in the HBV-X infected hepatoma which lacks functional p53 could lead to improved elimination of HCC.
Materials and methods
Cell culture, DNA transfection and CAT assays
Human hepatoma cells Hep3B, PLC/PRF/5, Huh7 and HepG2 were grown in a minimal essential medium supplemented with 10% fetal bovine serum. Human lung adenocarcinoma (A549) cells were grown in Dulbecco's modi®ed Eagle's medium (DMEM) with a high glucose content supplemented with 5% fetal bovine serum. Transfections were carried out by the CaPO 4 precipitation method (Graham and Vander Eb, 1973) . The CaPO 4 -DNA coprecipitate was established by overnight incubation. After medium change the cells were further incubated for 48 h in a complete medium. The cells were then harvested and extracts were assayed for CAT activity according to Gorman's method (Gorman et al., 1982) . Quantitative results were calculated by excising spots corresponding to nonacetylated and acetylated forms from the TLC plates, which were then counted in a liquid scintillation spectrophotometer (Beckman Co., USA).
Plasmid constructions
Adr subtype HBV DNA was isolated from HBV-infected Korean patients (Kim and Kang, 1894) . The intact X gene was prepared from the pHBV315-dimer plasmid which has two copies of HBV DNA cloned into the BamHI site of pBR322. For mammalian cell expression, X-ORF was cloned into the SalI site of pMAMneo (Clontech, CA, USA) (Kim et al., 1993) and designated as pMAMneo-X (Lee et al., 1998a,b) . Cells in 60-mm petri dishes coated with collagen (Gibco, Grand Island, NY, USA) were transfected with 10 mg of plasmid pMAMneo-X (previously linearized with EcoR) according to the calcium phosphate coprecipitation method. Transfectants were selected by culturing then in a-MEM medium containing 10% heat-inactivated FCS and 500 mg/ml G418 (Geneticin) (Sigma, St. Louis, MO, USA). G418-resistant colonies were isolated, replated twice and designated Hep3B-6X and 8X. Full length 2.4 kb human p21 promoterchloramphenicol acetyltransferase constructs as well as p21 promoter deletion constructs were provided by Drs Bert Vogelstein and Todd Waldman at the Johns Hopkins Oncology Center, USA. Four constructs were tested as follows: a 2.4 kb p21 promoter fragment containing the p21 transcription initiation start site at its 3'end and a p53 response element at the 5'end (D 0 ) a 1.5 kb fragment consisting of the 2.4 kb fragment from which 900 bp including the p53 response element had been deleted from the 5'end (D 2 ), a 1.2 kb fragment (D 3 ) and a 0.3 kb fragment (D 4 ) consisting of the 300 base pairs most proximal to the transcription start site (Waldman et al., 1995) . The Ets-CAT reporter construct was created by amplifying the p21 promoter region of cloned 72327 to +15 in p21-CAT plasmid with a 71411/71387 sense primer and a 79/+14 antisense primer to create a promoter fragment extending from 71411 to +14. PCR ampli®cation was for 1 min at 948C, 1 min at 508C, and 10 min at 608C. The PCR product was then treated with klenow fragment to creat blunt ends ligated into the HindIII-digested and klenow-treated SVO-CAT vector. The Ets site-speci®c promoter mutation construct, Etm-CAT, was created in a fashion analogous to that of Ets-CAT except that the 71425/71402 upstream sense primer contained the site-speci®c mutation underlined in the following sequence: 5'-TCAGCTGCGTTAGAGAGA-GAAGAC-3'. Human Ets-1 expression plasmid, pEts-1, was constructed with polymerase chain reaction fragments encoding the full-length sequence of Ets-1, in which Ets-1 proteins were expressed under the control of a human b-actin promoter.
Isolation of RNA and Northern blot analysis
Total RNA was prepared from the Hep3B cell line by extracting with acid guanidium thiocyanate-phenol-chloroform extraction as described (Chomzinski and Sacchi, 1987) . polyA + mRNA from the total RNA was puri®ed with an Oligotex mRNA kit (Qiagen, CA, USA). After quanti®cation by measuring absorbance at 260 and 280 nm, 1 mg of pure mRNA was electrophoresed on 1.2% agarose-formaldehyde gel containing 2% formaldehyde in 16MOPS buer and transferred onto nylon membrane (Hybond-N+, Amersham, USA) by capillary blotting. The 650 bp PCR fragment of p21 cDNA and the human b-actin probe were radiolabeled by the random primed DNA labeling method (Boehringer Mannheim, USA) with 50 mCi [a-32 P]dCTP. Prehybridization and hybridization with probes were performed for 16 h at 658C in 56SSC buer (16SSC: NaCl, 15 mM Na 3 -citrate) containing 56Denhardt's solution (16:0.02% ®coll, 0.02% polyvinylpyrrolidone, 0.02% serum albumin), 0.5% (w/v) sodium dodecyl sulfate and 1 mg/ml denatured salmon-sperm DNA. After washing two times in 26SSC, 0.1% (w/v) SDS at room temperature for 10 min, and once in 16SSC, 0.1% (w/v) SDS at 658C for 10 min, the ®lter was exposed overnight at 7808C to Kodak BioMax MR ®lm with an intensifying screen (Kodak, Japan). The probed membrane was stripped out by boiling twice in a solution of 0.5% (w/v) SDS, rehybridized with a 32 P-labeled human b-actin probe, and exposed overnight at 7808C.
Detection of DNA fragmentation and TUNEL assay DNA fragmentation was evaluated qualitatively by agarose gel electrophoresis. For DNA fragmentation assay subconuent Hep3B cells were transfected with 4 mg of pMAM-HX or treated with 20 mM vitamin K3 and lysed by lysis buer (10 mM Tris-HCl, pH 7.4, 100 mM NaCl, 25 mM EDTA, pH 8.0, 0.5% SDS, 0.1 mg/ml proteinase K) and incubated at 378C for 1 h. The lysates were extracted with phenol/ ammonium acetate at 7208C. After rinsing the resulting pellets with 70% ethanol, the remaining pellet was air-dried, dissolved into Tris-EDTA buer containing RNase (10 mg/ ml) and incubated at 378C for 1 h. In the presence of 0.1% SDS, 0.15 M NaCl, and 100 mg/ml proteinase K, the pellets were incubated at 378C for an additional 1 h and extracted with phenol/chloroform twice. After ethanol precipitation, the DNA pellet was dissolved in Tris-EDTA buer, and 3 mg of dissolved DNA was electrophoresed on 2% agarose gel containing ethidium bromide, and visualized by UV light. To con®rm the eect of HBV-X and VK3 on apoptosis, 1610 5 to 4610 5 cells were plated on coverships in 8-cm 2 plates and grown to 60 ± 80% con¯ueoncy. Cell were washed with PBS and ®xed in 100 ml paraformaldehyde solution (4% in PBS, pH 7.4) for 30 min at room temperature. After washing once with PBS, cells were permeabilized with 100 ml permeabilization buer (0.1% Triton X-100, 0.1% sodium citrate) for 2 min at 48C. The TUNE reaction was carried out by incubating cells in a moisture chamber for 1 h at 378C with TUNEL reaction mixture (Boehringer Mannhein, German) in a total reaction volume of 50 ml. After washing three times, samples were analysed under a¯uorescence microscope.
Histone H1 kinase assay
Transfected cells were washed twice with cold PBS and extraced on ice with 1 ml of Nonidet P-40 lysis buer (50 mM Tris, pH 7.5, containing 150 mM NaCl, 0.5% Nonidet P-40, 1 mM EDTA and protease inhibitors: 1 mM PMSF, 0.2 mM sodium orthovanadate, 1 mg/ml pepstain and leupeptin) for 30 min. Each extract was transferred to a microfuge tube and centrifuged at 10 000 g for 10 min 48C. The supernatant (200 mg total protein) was mixed with 2 mg of anti-CDK or anti-cyclin E (Santa Cruz Biotechnology) and rotated at 48C for 2 h. Immune-complexes were isolated by adding 30 ml of protein G plus/protein A-agarose (Calbiochem, MA, USA) rotated for an additional 3 h at 48C and precipitated by centrifugation for 3 min (16 000 g, 48C). After three washings with IP-washing buer (0.1% Nonidet P-40, 150 mM NaCl, 20 mM Tris, pH 7.5, 1 mM EDTA and proteinase inhibitors), the beads were washed with kinase buer (50 mM Tris, pH 7.5, 150 mM NaCl, 10 mM MgCl 2 , 1 mM DTT). The kinase reaction mixture contained 10 ml of histone H1 (100 mg/ml), 0.5 ml of [r-32 P]ATP (Amersham, 300 Ci/mmol), 1 mM ATP and 16kinase buer in 50 ml total volume.
Immunoprecipitation and immunoblotting
Cells were washed twice in ice-cold PBS, and lysed by scraping into lysis buer (50 mM Tris-HCl (pH 7.5), 150 mM sodium chloride, 1 mM EDTA, 1% NP-40 sodium deoxycholate, 1 mM sodium orthovanadate 25 mM sodium uoride, 2.5 mM phenylmethylsulfonyl¯uoride, 2.5 mg/ml leupeptin, and 2.5 mg/ml aprotinin) and were left on ice for 20 min. Lysates were centrifuged at 12 000 g for 15 min. For immunoprecipitation, cell lysates containing 500 mg of protein were incubated with 2 mg of p21 (clone DF10) antibody from Calbiochem (Cambridge, MA, USA) for 3 h at 48C. The immunocomplexes were incubated with Protein G plus/Protein A-agarose overnight at 48C. Immunocomplexes were washed three times with lysis buer. Proteins were subjected to 10% SDS ± PAGE and Western blotting. For immunoblotting, cell lysates containing 100 mg of protein were run on 10% SDS ± PAGE and transferred to nitrocellulose membrane (Stratagene, USA). Blots were blocked and incubated with antibodies in Tris-buered saline (10 mM Tris-HCI (pH 7.2) and 150 mM sodium chloride) containing 5% skim milk and 0.05% Tween 20. Antibodies against CDK-2 (clone D-12) and CDK-4 (clone H-22) were from Santa Cruz Biotechnology (Santa Cruz, CA, USA) and cyclin-E (clone HE-12) from Calbiochem (Cambridge, MA, USA). The signals were visualized using an ECL detection kit.
Detection of p21 by immunoprecipitation and Western blotting
Hep3B cells (1610 5 to 2610 6 ) transfected with pMAM-HX were lysed in 500 ml of ice cold IP buer (50 mM Tris-HCI pH 8, 150 mM NaCl, 1 mM phenylmethylsulfonyl¯uoride, 1 mg/ml aprotinin, 20 mM leupeptin, 0.1% SDS, and 1% NP-40). Protein concentration was measured by Biorad protein assay. After the same amount (1 mg) of each cell lysate was incubated with 2 mg of anti-p21 antibody (Ab-3; Calbiochem) for 2 h at 48C, precipitates were collected with 15 ml of protein G plus/protein A agarose (Calbiochem) for 1 h at 48C and washed four times with IP buer. The pellets were boiled in the sample buer (10% glycerol, 2% sodium dodecyl sulfate (SDS), 0.1 mM DTT, and 0.001% bromophenol blue) for 3 min, then separated in 14% SDS-polyacrylamide gel, transferred onto nitrocellulose membrane, and immunoblotted with goat polyclonal anti-p21 antibody, C-19 (Santa Cruz Biotech. Inc.) and horse radish peroxidase HRPconjugated anti-goat antibody. The bound antibody was visualized by chemilluminescence (ECL, Amersham).
Electrophoretic Mobility Shift Assay (EMSA)
Hep3B nuclear extracts were prepared as described. The oligonucleotide containing the ets binding sequence of the upstream region (71399 to 71392) of p21 wa¯/cipl gene and the mutant oligo (GGAA ? GAGA) were synthesized, annealed, and used as probes. The probes were end-labeled with g-32 P-ATP (Amersham Pharmacia Biotech) using T4 polynucleotide kinase (Takara, Japan). For the gel mobility shift assay, 10 mg of nuclear proteins and 50 000 c.p.m. of a 32 P-labeled probe were incubated at room temperature (228C) for 15 min with 1 mg of poly (dI-dC) (Sigma) in 20 ml of binding buer (20 nM Tris-HCI, pH 7.9, 50 mM NaCl, 10% glycerol, 3 mM MgCl 2 , 1 mM DTT, 1 mM EDTA). For the supershift assay subsequent to incubation of oligonucleotide probes with nuclear extracts, anti-Ets-1 (C-20, Sant Cruz Biotechnology) and anti-Ets-2 (C-20, San Cruz Biotechnology) antibodies were added to the reaction mixture and incubated for 1 h at room temperature (228C). DNA-protein complexes were resolved by electrophoresis through 5% polyacrylamide gel in 0.56TBE buer (45 mM Tris-borate and 1 mM EDTA) for 1.5 h at 200 V. After electorphoresis, the gel was dried and exposed to X-ray ®lms (Kodak).
Flow cytometric analysis of cell cycle
Cells were harvested and washed with sterilized PBS two times and stained with propidium iodide by resuspending in 30 mg/ml, 0.03% NP-40, 0.1% sodium citrate, and 11.25 u/ml Rnase (Sigma) and incubating for 30 min at RT. Stained cells were acquired on a FACScan and analysed with the Lysis software package.
Determination of growth rate
Cells (Hep3B, Hep3B-6X, and Hep3B-8X) were plated in 6-well plates (Nunc) and the total cell number in each well was counted everyday using a hemacytometer.
